$0.82
+0.04 (+4.55%)
Open$0.82
Previous Close$0.78
Day High$0.86
Day Low$0.78
52W High$3.68
52W Low$0.68
Volume—
Avg Volume21.8K
Market Cap10.42M
P/E Ratio—
EPS$-0.34
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,881.0% upside
Current
$0.82
$0.82
Target
$24.31
$24.31
$15.00
$24.31 avg
$29.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 356.3K | 1.99M | 1.82M |
| Net Income | -4,365,342 | -271,887 | -219,394 |
| Profit Margin | -1,227.1% | -13.7% | -12.0% |
| EBITDA | -4,210,805 | -443,981 | -374,843 |
| Free Cash Flow | — | -242,138 | -341,295 |
| Rev Growth | — | +6.4% | +1.5% |
| Debt/Equity | 0.07 | 0.27 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |